We are live on ! Find out more
FUSN icon

Fusion Pharmaceuticals

Delisted

FUSN was delisted on the 3rd of June, 2024.

41 hedge funds and large institutions have $130M invested in Fusion Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

0% more funds holding

Funds holding: 41 → 41 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.66% less ownership

Funds ownership: 73.02% → 72.37% (-0.66%)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

38% less capital inflows, than outflows

Capital inflows: $1.75M | Capital outflows: $2.82M

Holders
41
Holders Change
–
Holders Change %
0%
% of All Funds
0.65%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
4
Increased
8
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

FUSN Hedge Fund Activity: Q3 2023 in Review

41 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals (FUSN) for Q3 2023, worth a combined $130M — down 45% from $235M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new FUSN positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, adding an estimated $794K. The largest seller was Fidelity Investments, cutting an estimated $1.61M.

  • 41 institutional investors held Fusion Pharmaceuticals (FUSN) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $130M of Fusion Pharmaceuticals stock for Q3 2023, down 45% quarter-over-quarter.
  • 4 funds opened new Fusion Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of +1 holder.
  • The largest Fusion Pharmaceuticals buyer in Q3 2023 was Millennium Management, an estimated $794K added.
  • The largest Fusion Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $1.61M sold.

Based on aggregated 13F filings for Q3 2023.